Based on the key measurements obtained from MEI Pharma's financial statements, MEI Pharma is performing exceptionally good at this time. It has a great odds to report excellent financial results in March. At this time, MEI Pharma's Short and Long Term Debt Total is relatively stable compared to the past year. As of 02/01/2025, Property Plant And Equipment Gross is likely to grow to about 2.9 M, while Total Stockholder Equity is likely to drop slightly above 32.7 M. Key indicators impacting MEI Pharma's financial strength include:
The financial analysis of MEI Pharma is a critical element in measuring its lifeblood. Investors should not minimize MEI Pharma's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
MEI Pharma competes with Kezar Life, Vincerx Pharma, Avenue Therapeutics, Assembly Biosciences, and Instil Bio. MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Mei Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what MEI Pharma's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining MEI Pharma's current stock value. Our valuation model uses many indicators to compare MEI Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MEI Pharma competition to find correlations between indicators driving MEI Pharma's intrinsic value. More Info.
MEI Pharma is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.32 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for MEI Pharma is roughly 3.08 . At this time, MEI Pharma's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value MEI Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
MEI Pharma Systematic Risk
MEI Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. MEI Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on MEI Pharma correlated with the market. If Beta is less than 0 MEI Pharma generally moves in the opposite direction as compared to the market. If MEI Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one MEI Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of MEI Pharma is generally in the same direction as the market. If Beta > 1 MEI Pharma moves generally in the same direction as, but more than the movement of the benchmark.
MEI Pharma Thematic Clasifications
MEI Pharma is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in MEI Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various MEI Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of MEI Pharma growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of MEI Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of MEI Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of MEI Pharma based on widely used predictive technical indicators. In general, we focus on analyzing MEI Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build MEI Pharma's daily price indicators and compare them against related drivers.
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.